Zobrazeno 1 - 5
of 5
pro vyhledávání: '"R. F. Grube"'
Autor:
Wolfgang Heinlein, M Rathmayer, Andreas Stallmach, R. F. Grube, Michael Wilke, Markus M. Lerch, Wolfgang Schepp, Ansgar W. Lohse, für die DRG-Arbeitsgruppe und das Zeiterfassungsprojekt der Dgvs, H. Scheffer
Publikováno v:
Zeitschrift für Gastroenterologie. 53:391-397
Hintergrund: Die Clostridium-difficile-assoziierte Diarrho (CDAD) stellt ein zunehmendes medizinisches und gesundheitsokonomisches Problem dar. Methodik: Im DRG-Projekt der Deutschen Gesellschaft fur Verdauungs- und Stoffwechselkrankheiten wurden in
Publikováno v:
European Journal of Medical Research
European Journal of Medical Research, Vol 16, Iss 7, p 315 (2011)
European Journal of Medical Research, Vol 16, Iss 7, p 315 (2011)
Introduction Hospital-acquired pneumonia (HAP) often occurring as ventilator-associated pneumonia (VAP) is the most frequent hospital infection in intensive care units (ICU). Early adequate antimicrobial therapy is an essential determinant of clinica
Autor:
R F, Grube, W, Heinlein, H, Scheffer, M, Rathmayer, W, Schepp, A W, Lohse, A, Stallmach, M H, Wilke, M M, Lerch
Publikováno v:
Zeitschrift fur Gastroenterologie. 53(5)
Clostridium difficile associated diarrhea (CDAD) is not only a increasing medical but also economical problem.Data from the DRG project group of the German society for digestive and metabolic diseases (DGVS) were analyzed for CDAD. Out of 430,875 cas
Publikováno v:
European Journal of Medical Research, Vol 16, Iss 12, p 543 (2011)
European Journal of Medical Research
European Journal of Medical Research
Introduction The management of bloodstream infections especially sepsis is a difficult task. An optimal antibiotic therapy (ABX) is paramount for success. Procalcitonin (PCT) is a well investigated biomarker that allows close monitoring of the infect
Autor:
Michael Wilke, R F Grube
Publikováno v:
European Journal of Medical Research, Vol 15, Iss 12, p 564 (2010)
European Journal of Medical Research
European Journal of Medical Research
The cost of treatments especially in conditions where multiresistant bacteria are involved are a major issue in times where in most developed countries in the world payment systems based on diagnoses-related-groups (DRG) are in place. There is great